Trans-Arterial Radioembolization with Yttrium-90 of Unresectable and Systemic Chemotherapy Resistant Hepatoblastoma in Three Toddlers.

Autor: Balli HT; Department of Radiology, Cukurova University Medical School, Balcali Hospital, Adana, Turkey., Aikimbaev K; Department of Radiology, Cukurova University Medical School, Balcali Hospital, Adana, Turkey., Guney IB; Department of Nuclear Medicine, Cukurova University Medical School, Balcali Hospital, Adana, Turkey., Piskin FC; Department of Radiology, Cukurova University Medical School, Balcali Hospital, Adana, Turkey. ferhatcpiskin@gmail.com., Yagci-Kupeli B; Department of Pediatric Hematology and Oncology, University of Health Sciences, Adana Education and Research Center, Adana, Turkey., Kupeli S; Department of Pediatric Oncology, Cukurova University Medical School, Balcali Hospital, Adana, Turkey., Kanmaz T; Department of Pediatric Surgery, Organ Transplantation Center, Koc University Hospital, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2022 Mar; Vol. 45 (3), pp. 344-348. Date of Electronic Publication: 2022 Jan 16.
DOI: 10.1007/s00270-021-03026-6
Abstrakt: The aim of this short communication was to report the results of transarterial radioembolization (TARE) with Yttrium-90 (Y90) loaded resin microspheres in three toddlers with unresectable and systemic chemotherapy-resistant HB hepatoblastoma (HB). Six TARE procedures were performed on the patients. The dose required for treatment was calculated using partition model. Administered doses of Y90 were 1.369, 0.851, and 1.147 GBq. Complete radiological response in two patients and partial response enabling liver resection in one patient were achieved. Neither life-threatening nor minor complications developed after the treatment. These results demonstrates that HB is a radiosensitive neoplasm, and TARE-Y90 can be used as the primary, neoadjuvant and palliative treatment method in patients with unresectable and systemic chemotherapy-resistant HBs. However, studies with higher number of patients and long-term results are required.
(© 2021. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).)
Databáze: MEDLINE
Externí odkaz: